International survey of treatment practices for atopic dermatitis in pregnant and breastfeeding women: Physician perspectives.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pereira Manuel P, Stevanovic Katarina, Kocatürk Emek, Meesch Cathrin, van Hofman Ingrid, Vaswani Prema S, Bernstein Jonathan A, Bruscky Dayanne, Chong-Neto Herberto J, Chu Chia-Yu, Criado Roberta Fachini Jardim, Ensina Luis Felipe, Giménez-Arnau Ana M, Godse Kiran, Gotua Maia, Gregoriou Stamatios, Kulthanan Kanokvalai, Mortz Charlotte G, Mitrevska Natasa Teovska, Özkaya Esen, Pudasaini Prajwal, Felix Mara Morelo Rocha, Pérez Catalina Rincón, Parisi Claudio Alberto Salvador, Ramón Gonzalo N, Vakirlis Efstratios, Zhao Zuotao, Beck Lisa A, de Bruin-Weller Marjolein, Cork Michael, Katoh Norito, Werfel Thomas, Worm Margitta, Wollenberg Andreas, Zuberbier Torsten
Аннотация
PATIENTS AND METHODS: The Global Allergy and Asthma Excellence Network (GA2LEN) ADCARE initiative collected data from physicians worldwide who treat pregnant women with AD. Physicians completed an electronic questionnaire on the use of systemic agents in pregnant/breastfeeding AD patients.
RESULTS: 103 physicians from 32 countries completed the survey, primarily dermatologists (n = 48) or allergologists (n = 43). Antihistamines were the systemic drug most often considered to be used during pregnancy/breastfeeding (n = 73/81, 90.1%), with fewer physicians considering the use of systemic agents for the first trimester compared to later stages of pregnancy. For acute flares, systemic corticosteroids (n = 34/80, 42.5%) were preferred, followed by biologics and antihistamines (each n = 15/80, 18.8%). Although the guideline-recommended cyclosporine is sometimes considered for AD during pregnancy (n = 38/81, 46.9%), it was rarely considered as the preferred drug by physicians (n = 1/80, 1.25%).
CONCLUSIONS: Our study shows a misalignment between guideline recommendations and prescription patterns and highlights an unmet need for knowing and using the existing recommendations.